CP
BCRX icon

Castleview Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Castleview Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36
Closed -$413 – 672
2022
Q4 		$413 Buy
+36
New +$449 ﹤0.01% 586

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Castleview Partners's BCRX Position: Q1 2023 in Review

Castleview Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 36 shares — an estimated $413 sold.

Castleview Partners first reported a position in BCRX in Q4 2022 and held it in 1 quarter. The position peaked at $413 in Q4 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Castleview Partners reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Castleview Partners sold 36 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $413.
  • Castleview Partners first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Castleview Partners's BioCryst Pharmaceuticals position peaked at $413 in Q4 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.